Premium
Clinical comparison of the nitrosoureas
Author(s) -
Wasserman Todd H.,
Slavik Milan,
Carter Stephen K.
Publication year - 1975
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197510)36:4<1258::aid-cncr2820360411>3.0.co;2-6
Subject(s) - nitrosourea , lomustine , clinical trial , medicine , carmustine , cancer , oncology , medical physics , chemotherapy , cyclophosphamide , vincristine
The nitrosourea group of antitumor agents was developed by the Division of Cancer Treatment of the National Cancer Institute. Three nitrosoureas (BCNU, CCNU, MeCCNU) have undergone extensive clinical trials, and two of them (BCNU, CCNU) will soon become commercially available. This paper briefly considers the preclinical development of the nitrosoureas and provides an overview and comparison of the extensive clinical data. Information is given regarding any clinical differences. We discuss general conclusions drawn from the nitrosourea development.